In recognition of SVT Awareness Day, the Heart Rhythm Society (HRS) and Milestone Pharmaceuticals are partnering to expand ...

Patients presenting to the emergency department with apparent supraventricular tachycardia (SVT) need prompt follow-up with consideration for screening for atrial fibrillation (AF), especially those ...

Untreated or unmanaged, SVT can lead to other possibly fatal heart abnormalities. Patients are advised to practice a cardiac-friendly diet and lifestyle (low sodium, little to no caffeine or alcohol, ...

MADISON, WI — The American College of Cardiology, American Heart Association, and the Heart Rhythm Society (ACC/AHA/HRS) have published new guidelines for the management of patients with ...

Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...

AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK(R) (landiolol) for use in pediatric patients (from birth to <18 years of age) with ...

(HealthDay News) — For patients with symptomatic supraventricular tachycardia (SVT), caffeine is associated with increases in systolic and diastolic blood pressure, but does not impact cardiac ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer and tachycardia had an increased risk for mortality near the time of treatment, according ...

A drug approved to treat chest pain reduces the incidence of a common arrhythmia called ventricular tachycardia in patients with an implantable cardioverter defibrillator (ICD), according to a study ...

(HealthDay News) — For patients with cancer, tachycardia can predict the risk for mortality, according to a study presented at the Advancing the Cardiovascular Care of the Oncology Patient conference ...

AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK® (landiolol) for use in pediatric patients (from birth to <18 years of age) with ...